Feasibility of assessing quality in medical oncology practices

Cancer Practice

Volumn 9, Issue 5, 2001, Pages 231-235

  Cornfeld, Mark J ^a   Jadwin, Anne ^a   O'Grady, Peg ^a   Babb, Jim ^a   Engstrom, Paul F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Clinical trials; Medical oncology; Neutropenia; Quality assurance

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HORMONE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CERTIFICATION; CLINICAL PROTOCOL; CONTINUING EDUCATION; HEALTH CARE QUALITY; HUMAN; MEDICAL PRACTICE; MEDICAL SPECIALIST; NEUTROPENIA; ONCOLOGY; PATIENT CARE; PATIENT SATISFACTION; QUALITY CONTROL; SEPSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; MEDICAL ONCOLOGY; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY INDICATORS, HEALTH CARE;

EID: 0034834140     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.2001.009005231.x     Document Type: Article

References (17)

1. NCI to expand quality of care research, lead HHS panel on cancer care policy
2. Performance measurement in cancer care: Uses and challenges
3. Managed oncology care: The disease measurement model
4. What the private sector does not know about purchasing ontology services
5. Proposed agenda for the measurement of quality-of-care outcomes in oncology practice
6. Unreliability of physician "report cards" to assess cost and quality of care
7. Quality improvement: Carrots or sticks?
8. Peer review of the quality of care: Reliability, and sources of variability for outcome and process assessments
9. Evaluating the quality of medical care
10. American Society of Clinical 1998 update of recommended breast cancer surveillance guidelines
11. Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy
12. Update: NCCN practice guidelines for the treatment of breast cancer
13. Incidence of emergency visits among oncology patients receiving outpatient chemotherapy: Implications for care in a capitated market